XNAS
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Q1 2026 | -0.09 | -0.09 | +0.00% | $25.0M | ➖ Inline | +0.00% | +21.43% | — |
| 2026-03-11 | Q4 2025 | -0.12 | -0.12 | +0.00% | $0 | ➖ Inline | -3.34% | -4.22% | -19.65% |
| 2025-11-10 |
| Q3 2025 |
| -0.15 |
| -0.12 |
| +20.00% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | -0.19 | -0.14 | +26.32% | $0 | ✅ Beat | +1.54% | +27.65% | +100.12% |
| 2025-03-10 | Q4 2024 | -0.31 | -0.28 | +9.68% | $0 | ✅ Beat | +6.78% | +44.35% | -10.58% |
| 2024-05-14 | Q1 2024 | -0.42 | -0.40 | +4.76% | $0 | ✅ Beat | -3.41% | -5.00% | -15.00% |
| 2024-03-18 | Q4 2023 | -0.44 | -0.40 | +9.09% | $0 | ✅ Beat | — | — | — |
| 2023-11-08 | Q3 2023 | -0.47 | -0.39 | +17.02% | $0 | ✅ Beat | -3.57% | -7.14% | +1.53% |
Showing last 8 quarters.